Key statistics
Short selling activityProvided by S&P Global Market Intelligence
| Open | -- |
|---|---|
| High | -- |
| Low | -- |
| Bid | -- |
| Offer | -- |
| Previous close | -- |
| Average volume | -- |
|---|---|
| Shares outstanding | 10.88bn |
| Free float | 10.40bn |
| P/E (TTM) | -- |
| Market cap | 97.88m AUD |
| EPS (TTM) | -0.002 AUD |
Data delayed at least 15 minutes.
More ▼
Announcements
- Alterity Therapeutics: Appendix 4C – Q2 FY26 Quarterly Cash Flow Report & Corporate Update
- Alterity Therapeutics Issues Shareholder Letter Highlighting 2025 Progress and Key Objectives for 2026
- Alterity Therapeutics to Present at the Bell Potter Healthcare Virtual Conference
- Alterity Therapeutics Presents Promising Impact of ATH434 on Orthostatic Hypotension and Disease Progression in MSA at the 36th International Symposium on the Autonomic Nervous System
- Alterity Therapeutics: Appendix 4C – Q1 FY26 Quarterly Cash Flow Report
- Alterity Therapeutics Presents Positive Data from ATH434 Phase 2 Trial at the 2025 International Congress of Parkinson’s Disease and Movement Disorders
- Alterity Therapeutics to Deliver Multiple Presentations at the 2025 International Congress of Parkinson’s Disease and Movement Disorders
- Alterity Therapeutics Presents ATH434-201 Phase 2 Data at the American Neurological Association Annual Meeting
- Alterity Therapeutics Raises A$20.0 million in Strategic Placement
- Alterity Therapeutics to Present at the Biotech Showcase
More ▼
